- Home
- GROV vs ANL Comparison
GROV vs ANL Comparison
Compare GROV & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROV
- ANL
- Stock Information
- Founded
- GROV 2016
- ANL 2004
- Country
- GROV United States
- ANL Cayman Islands
- Employees
- GROV N/A
- ANL N/A
- Industry
- GROV Package Goods/Cosmetics
- ANL
- Sector
- GROV Consumer Discretionary
- ANL
- Exchange
- GROV Nasdaq
- ANL Nasdaq
- Market Cap
- GROV 53.5M
- ANL 61.8M
- IPO Year
- GROV N/A
- ANL 2023
- Fundamental
- Price
- GROV $1.54
- ANL $1.79
- Analyst Decision
- GROV Buy
- ANL Hold
- Analyst Count
- GROV 2
- ANL 1
- Target Price
- GROV $1.35
- ANL N/A
- AVG Volume (30 Days)
- GROV 51.9K
- ANL 9.3K
- Earning Date
- GROV 11-11-2025
- ANL 09-26-2025
- Dividend Yield
- GROV N/A
- ANL N/A
- EPS Growth
- GROV N/A
- ANL N/A
- EPS
- GROV N/A
- ANL N/A
- Revenue
- GROV $185,354,000.00
- ANL N/A
- Revenue This Year
- GROV N/A
- ANL N/A
- Revenue Next Year
- GROV $11.10
- ANL N/A
- P/E Ratio
- GROV N/A
- ANL N/A
- Revenue Growth
- GROV N/A
- ANL N/A
- 52 Week Low
- GROV $1.02
- ANL $1.10
- 52 Week High
- GROV $1.95
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- GROV 57.35
- ANL 60.57
- Support Level
- GROV $1.49
- ANL $1.65
- Resistance Level
- GROV $1.59
- ANL $1.91
- Average True Range (ATR)
- GROV 0.04
- ANL 0.10
- MACD
- GROV -0.00
- ANL 0.00
- Stochastic Oscillator
- GROV 50.00
- ANL 58.02
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.